

August 25, 2022**Contents**

Clinical Profile Documentation	2
AJCC 8 th Edition Staging	2
Biomarker Guidance	2
Problems	3
Additions	3
Updates	3
Billing & HCPCS Codes	3
Updates	3
Lab Analytes and Panels	4
Additions	4
Medications	4
Additions	4
Updates	5
Regimens	5
Additions	6
Updates	6
Research	7
Updates	7
Appendix A	8
Problem & Codes Summary	8
Appendix B	22
Regimen Consolidation Summary	22
Updates	22
Removals	23

Clinical Profile Documentation

AJCC 8th Edition Staging

This release contains updated **TNM** values, **Stage Groupings**, and **Template** functionality for:

- **Fallopian Tube Cancer**
- **Ovarian Cancer**
- **Primary Peritoneal Cancer**

Users will see updates to the **Distant Metastasis (M)** documentation points for **Ovarian cancer**, **Primary Peritoneal cancer**, and **Fallopian Tube cancer**:

- **cM1a** is no longer available
- **cM1** and **pM1** are available and valid when the M1 subcategory is not specified

The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Biomarker Guidance

A new informational row called **BIOMARKER TESTING** will display NCCN biomarker testing guidelines for non-small cell lung cancer in the Details section, when adding a new Problem in a patient's Clinical Profile. This information can be used to place biomarker testing in the Orders tab.

This feature is part of an effort to support biomarker testing and optimize your patients' treatment plans in iKnowMed.

New Problem		Staging ⊕ Add a Stage		BIOMARKER TESTING [Stage IB: EGFR] [Stages IIA-IIIa: EGFR+PD-L1] [Metastatic: PD-L1 + Comprehensive Genomic Profiling]
Problem (required)	Non-small cell lung cancer (disorder)	Stage Date	08/19/2022	
Date of Diagnosis		Staging Type	Pathological	
Status	Active	Location	Left main bronchus	
Comment		Tumor Type	T2a	
Details	Stage: IVA, Stage Date 08/19/2022, Staging Type: Pathological, Location: Left main bronchus, Tumor Type: T2a, Node: N2, Metastasis: M1b	Node	N2	
ICD-10	C34.02 - Malignant neoplasm of left main bronchus	Metastasis	M1b	
Additional Codes	Tobacco/Nicotine use (needs coding)	BIOMARKER TESTING [Stage IB: EGFR] [Stages IIA-IIIa: EGFR+PD-L1] [Metastatic: PD-L1 + Comprehensive Genomic Profiling]		
		Stage	IVA	

Problems

Additions

The following items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes* may be displayed to present the surrounding nodes.

- **Castleman's disease**

Please see **APPENDIX A** for a complete summary of changes.

Updates

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses:

Oropharyngeal Cancer, Human Papilloma no longer contains the following documentation point:

- **HPV-18 positive**

Myelofibrosis has been assigned a **pathway (PW)** designation to ensure documentation remains synonymous with clinical decision support and ICD-10 mapping. The following problems now have **PW** to the left of the problem in the search results:

- Acute myelofibrosis (disorder)
- Acute panmyelosis w myelofibrosis, in relapse
- Acute panmyelosis w myelofibrosis, in remission
- Congenital neutropenia, myelofibrosis, nephromegaly syndrome
- Ischaemic myelofibrosis
- Myelofibrosis
- Myelofibrosis caused by drug
- Myelofibrosis due to and following essential thrombocytopenia
- Myelofibrosis due to and following polycythemia vera
- Myelofibrosis w myeloid metaplasia
- Secondary myelofibrosis

Billing & HCPCS Codes

Updates

Bortezomib Billing Guidance – Per CMS, the HCPCS billing code for **Bortezomib** has changed to **J3490** backdating to the first of July. The code is now available but may not generate on charge capture. If you find the billing code is incorrect, billing considerations can be used. Please use billing considerations for this brand only:

- Dr. Reddy's Laboratories, Inc., NDC 43598086560

Lab Analytes and Panels

Additions

- ANA screen w/ reflex to titer
- Cabot rings WAM
- CMI173-PD-1 panel
- Coarse speckled
- COVID/Flu/RSV panel
- CYTO. reticular (MITO)
- Dense fine speckled
- Discrete nuclear dots
- Influenza A, PCR
- Influenza B, PCR
- Insulin panel
- Insulin, 120 minutes post dose
- Insulin, 30 minutes post dose
- Insulin, 60 minutes post dose
- Insulin, 90 minutes post dose
- Insulin, fasting
- Invitae adenomatous polyposis panel
- Invitae adenomatous polyposis results
- Invitae chronic pancreatitis panel + Invitae multi-cancer panel
- Invitae chronic pancreatitis panel + Invitae multi-cancer panel results
- Invitae ehlers-danlos syndrome panel + Invitae marfan syndrome test
- Invitae ehlers-danlos syndrome panel + Invitae marfan syndrome test result
- Invitae multi-cancer panel + GALNT12 + RNF43 + RPS20
- Invitae multi-cancer panel + Invitae BRCA1/2 panel
- Invitae multi-cancer panel + Invitae BRCA1/2 panel results
- Invitae multi-cancer panel + Invitae familial adenomatous polyposis test
- Invitae multi-cancer panel + Invitae familial adenomatous polyposis test result
- Invitae multi-cancer panel + MC1R
- Invitae multi-cancer panel + MC1R results
- Luteinizing hormone, IU/L
- Rapid SARS-COV-2, PCR
- Rh(D) genotype
- RSV, PCR
- SARS-COV-2 CT value
- Transcriptome detection_v1 panel, hybrid

Medications

Additions

- BDTX-1535 invest Oral
- DZD9008 invest Oral
- JANX007 invest IV
- LP035 invest Buccal Film
- MTB-9655 invest Oral
- Nature Throid Oral
- PF-07265028 invest Oral
- PRT811 invest Oral
- Q901 invest IV
- SIM1811-03 invest IV
- Troriluzole (BHV-4157) invest Oral
- TU2218 invest Oral
- Tusamitamab Ravtansine invest (SAR408701 invest IV)
- VT1021 invest IV
- XmAb20717 invest IV
- Zimberelimab invest (AB122 invest IV)

Updates

Medication	Update
ABI-009 invest IV	New Brand-name available: Nab-sirolimus invest (ABI-009 invest IV)
Skyrizi (Risankizumab-rzaa IV)	New default Sig : Risankizumab-rzaa 600 mg intravenously Piggyback once; Dilute with 100-500 mL D5W to a final concentration 1.2-6 mg/mL. Administer over at least 1 hour. Complete infusion within 8 hours of dilution. Do not administer with other agents. Do not shake. <ul style="list-style-type: none"> Updated Max Single Dose: 600 mg
NC318 invest IV	New Form available: 400 mg recon soln
Abemaciclib invest (LY2835219 invest Oral)	New Form(s) available: <ul style="list-style-type: none"> 100 mg tablet 150 mg tablet
Palbociclib invest Oral	New Forms available: <ul style="list-style-type: none"> 75 mg tablet 100 mg tablet 125 mg tablet
Vinblastine IV	Updated Max Single Dose : 17 mg
Elacestrant invest (RAD1901 invest Oral)	<ul style="list-style-type: none"> New Instructions available: IP must be stored at controlled room temperature 20-25 degree C (68-77degree F). New Frequency available: daily
Pemetrexed IV	New default Sig : 500 mg/m ² intravenously Piggyback once; administer over 10 minutes; Dilute with NS to a total volume of 100 mL.
Sasanlimab invest Subcutaneous	New Sig available: 300 mg subcutaneously every 4 weeks

Regimens

This section does not include clinical trial regimens.

Biosimilar and Reference Regimens

To improve ease of ordering, the Collaborative Care Committee (CCC) recently voted to merge separate biosimilar and reference regimens into single regimen templates. These updates will occur in a rolling fashion over the next several months.

This release contains the consolidation of all bevacizumab regimen templates and the addition of a new bevacizumab biosimilar (**Alymsys**). For a list of all merged bevacizumab regimens please refer to **APPENDIX B**.

Additions

Regimen Name	Diagnosis
Bendamustine (90 mg/m ²) D1,2 Q28D (CAR T-cell Therapy Lymphodepletion)	Leukemia, Acute Lymphocytic (ALL), Lymphoma, Non-Hodgkin (NHL) (Parent), Multiple Myeloma (MM)
Docetaxel + Abiraterone + Prednisone + ADT Q3M (Abiraterone + Prednisone + Goserelin only)	Prostate Cancer
Docetaxel + Abiraterone + Prednisone + ADT Q3M (Abiraterone + Prednisone + Leuprolide only)	Prostate Cancer
Docetaxel + Darolutamide + ADT Q3M (Darolutamide + Goserelin only)	Prostate Cancer
Docetaxel + Darolutamide + ADT Q3M (Darolutamide + Leuprolide only)	Prostate Cancer
FOLFIRINOX + Panitumumab Q14D	Colon Cancer, Rectal Cancer
Ibrutinib (3 cycles) fb Ibrutinib + Venetoclax Q28D (12 cycles) (CLL)	Leukemia, Chronic Lymphocytic (CLL), Lymphoma, Non-Hodgkin (NHL) (Parent)
Obinutuzumab + Lenalidomide D1-21 Q28D	Lymphoma, Non-Hodgkin (NHL) (Parent)
Risankizumab-rzza IV D1,28,56 (Crohn's Induction)	Crohn's Disease

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference updates, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Brain Tumor (Parent)
- Cervical Cancer
- Colon Cancer
- Fallopian Tube Cancer
- Hepatocellular Carcinoma (HCC)
- Lung Cancer, Non-small Cell (NSCLC)

- Malignant Mesothelioma
- Malignant Pleural Mesothelioma
- Ovarian and Primary Peritoneal Cancer
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Uterine Cancer (Parent)

Research

Updates

The USOR Clinical Trials listed in the table below are updated:

	Updated Reference Information			
		Updated Drug Service Order Information		
		Updated Regimen Instructions		
				Other Changes
USOR 16104	X			
USOR 18126	X			
USOR 18283		X		No longer available: <ul style="list-style-type: none"> • USOR 18283 Sacituzumab govitecan (IMMU-132) D1,8 Q21D
USOR 19113		X	X	
USOR 20136				Now available: <ul style="list-style-type: none"> • USOR 20169 TAK-981 D1,8 + Rituximab IV Q21D No longer available: <ul style="list-style-type: none"> • USOR 20169 TAK-981 D1,8,15 + Rituximab IV Q21D
USOR 20138	X	X		
USOR 20175	X	X	X	
USOR 20176		X		
USOR 20189	X			
USOR 20229	X			
USOR 20363	X	X		
USOR 20388	X			

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
			Other Changes	
USOR 20398	X		X	Now available: <ul style="list-style-type: none"> • USOR 20398 Giredestrant (PO; Daily) + Abemaciclib (PO; BID) Q28D • USOR 20398 Inavolisib (PO; Daily) + Palbociclib (PO; D1-21) Q28D • USOR 20398 Inavolisib (PO; Daily) + Palbociclib (PO; D1-21) + Letrozole (PO; Daily) Q28D • USOR 20398 Inavolisib (PO; Daily) + Olaparib (PO; BID) Q28D
USOR 20409	X	X	X	
USOR 21171	X	X	X	
USOR 21219	X	X	X	
USOR 21235		X	X	
USOR 21239	X	X	X	
USOR 21326		X	X	No longer available: <ul style="list-style-type: none"> • USOR 21326 Part 1 Bemarituzumab + Nivolumab + mFOLFOX6 Q14D
USOR 21346	X	X	X	Now available: <ul style="list-style-type: none"> • USOR 21346 Part 5 VIP152 D1,8,15 Q21D
USOR 21378		X		
USOR 21536		X		
USOR 21537		X		

Appendix A

Problem & Codes Summary

Problem	ICD-10 Code(s)*
Abdominal distension (gaseous)	R14.0 Abdominal distension (gaseous)
Abnormal bleeding of cervix	N88.8 Other specified noninflammatory disorders of cervix uteri

Abnormal findings on diagnostic imaging of gastrointestinal tract	R93.3 Abnormal findings on diagnostic imaging of other parts of digestive tract
Abscess of breast (disorder)	N61.1 Abscess of the breast and nipple
Abscess of ischiorectal fossa	K61.39 Other ischiorectal abscess
Abscess of liver (disorder)	K75.0 Abscess of liver
Abscess of lower limb (disorder)	L02.415 Cutaneous abscess of right lower limb L02.416 Cutaneous abscess of left lower limb L02.419 Cutaneous abscess of limb, unspecified
Abscess of nipple (disorder)	N61.1 Abscess of the breast and nipple
Acute anal fissure (disorder)	K60.0 Acute anal fissure
Acute appendicitis (disorder)	K35.80 Unspecified acute appendicitis
Acute appendicitis without peritonitis (disorder)	K35.80 Unspecified acute appendicitis
Acute duodenal ulcer with hemorrhage (disorder)	K26.0 Acute duodenal ulcer with hemorrhage
Acute gastric ulcer (disorder)	K25.0 Acute gastric ulcer with hemorrhage K25.1 Acute gastric ulcer with perforation K25.2 Acute gastric ulcer with both hemorrhage and perforation K25.3 Acute gastric ulcer without hemorrhage or perforation
Acute gastritis with bleeding	K29.01 Acute gastritis with bleeding
Anal polyp (disorder)	K62.0 Anal polyp
Anal skin tag (disorder)	K64.4 Residual hemorrhoidal skin tags
Anal spasm (disorder)	K59.4 Anal spasm
Anogenital molluscum contagiosum	B08.1 Molluscum contagiosum
Anorectal fistula (disorder)	K60.5 Anorectal fistula
Appendicitis (disorder)	K37 Unspecified appendicitis
ASC-H pap smear	R87.611 Atypical squamous cells cannot exclude high grade squamous intraepithelial lesion on cytologic smear of cervix (ASC-H)
ASC-US pap smear	R87.610 Atypical squamous cells of undetermined significance on cytologic smear of cervix (ASC-US)
Barium enema abnormal (finding)	R93.3 Abnormal findings on diagnostic imaging of other parts of digestive tract
Benign neoplasm of anal canal (disorder)	D12.9 Benign neoplasm of anus and anal canal
Benign neoplasm of anus (disorder)	D12.9 Benign neoplasm of anus and anal canal
Benign neoplasm of appendix (disorder)	D12.1 Benign neoplasm of appendix

Benign neoplasm of ascending colon (disorder)	D12.2 Benign neoplasm of ascending colon
Benign neoplasm of colon (disorder)	D12.6 Benign neoplasm of colon, unspecified
Benign neoplasm of descending colon (disorder)	D12.4 Benign neoplasm of descending colon
Benign neoplasm of perianal skin (disorder)	D23.5 Other benign neoplasm of skin of trunk
Benign neoplasm of sigmoid colon (disorder)	D12.5 Benign neoplasm of sigmoid colon
Bilateral inguinal hernia (disorder)	K40.00 Bilateral inguinal hernia, with obstruction, without gangrene, not specified as recurrent K40.01 Bilateral inguinal hernia, with obstruction, without gangrene, recurrent K40.10 Bilateral inguinal hernia, with gangrene, not specified as recurrent K40.11 Bilateral inguinal hernia, with gangrene, recurrent K40.20 Bilateral inguinal hernia, without obstruction or gangrene, not specified as recurrent K40.21 Bilateral inguinal hernia, without obstruction or gangrene, recurrent
Candidiasis of nails (disorder)	B37.2 Candidiasis of skin and nail
Candidiasis of skin (disorder)	B37.2 Candidiasis of skin and nail
Carcinoid syndrome (disorder)	E34.0 Carcinoid syndrome
Castleman's disease (disorder)	D47.Z2 Castleman disease
Cellulitis (disorder)	L03.90 Cellulitis, unspecified
Cervical intraepithelial neoplasia grade 2 (disorder)	N87.1 Moderate cervical dysplasia
Cholecystitis (disorder)	K81.9 Cholecystitis, unspecified
Cholesterolosis of gallbladder (disorder)	K82.4 Cholesterolosis of gallbladder
Chronic cholecystitis (disorder)	K81.1 Chronic cholecystitis
Chronic gastric ulcer (disorder)	K25.4 Chronic or unspecified gastric ulcer with hemorrhage K25.5 Chronic or unspecified gastric ulcer with perforation K25.6 Chronic or unspecified gastric ulcer with both hemorrhage and perforation K25.7 Chronic gastric ulcer without hemorrhage or perforation
Chronic gastric ulcer with hemorrhage (disorder)	K25.4 Chronic or unspecified gastric ulcer with hemorrhage
Chronic pancreatitis NOS	K86.1 Other chronic pancreatitis

Chronic ulcerative pancolitis (disorder)	<p>K51.00 Ulcerative (chronic) pancolitis without complications</p> <p>K51.011 Ulcerative (chronic) pancolitis with rectal bleeding</p> <p>K51.012 Ulcerative (chronic) pancolitis with intestinal obstruction</p> <p>K51.013 Ulcerative (chronic) pancolitis with fistula</p> <p>K51.014 Ulcerative (chronic) pancolitis with abscess</p> <p>K51.018 Ulcerative (chronic) pancolitis with other complication</p> <p>K51.019 Ulcerative (chronic) pancolitis with unspecified complications</p>
Chronic ulcerative proctitis (disorder)	<p>K51.20 Ulcerative (chronic) proctitis without complications</p> <p>K51.211 Ulcerative (chronic) proctitis with rectal bleeding</p> <p>K51.212 Ulcerative (chronic) proctitis with intestinal obstruction</p> <p>K51.213 Ulcerative (chronic) proctitis with fistula</p> <p>K51.214 Ulcerative (chronic) proctitis with abscess</p> <p>K51.218 Ulcerative (chronic) proctitis with other complication</p> <p>K51.219 Ulcerative (chronic) proctitis with unspecified complications</p>
Closed fracture of left forearm (disorder)	<p>S52.92XA Unspecified fracture of left forearm, initial encounter for closed fracture</p> <p>S52.92XD Unspecified fracture of left forearm, subsequent encounter for closed fracture with routine healing</p> <p>S52.92XG Unspecified fracture of left forearm, subsequent encounter for closed fracture with delayed healing</p> <p>S52.92XK Unspecified fracture of left forearm, subsequent encounter for closed fracture with nonunion</p> <p>S52.92XP Unspecified fracture of left forearm, subsequent encounter for closed fracture with malunion</p> <p>S52.92XS Unspecified fracture of left forearm, sequela</p>
Closed fracture of multiple ribs (disorder)	<p>S22.41XA Multiple fractures of ribs, right side, initial encounter for closed fracture</p> <p>S22.41XD Multiple fractures of ribs, right side, subsequent encounter for fracture with routine healing</p> <p>S22.41XG Multiple fractures of ribs, right side, subsequent encounter for fracture with delayed healing</p> <p>S22.41XK Multiple fractures of ribs, right side, subsequent encounter for fracture with nonunion</p> <p>S22.41XS Multiple fractures of ribs, right side, sequela</p>

	<p>S22.42XA Multiple fractures of ribs, left side, initial encounter for closed fracture</p> <p>S22.42XD Multiple fractures of ribs, left side, subsequent encounter for fracture with routine healing</p> <p>S22.42XG Multiple fractures of ribs, left side, subsequent encounter for fracture with delayed healing</p> <p>S22.42XK Multiple fractures of ribs, left side, subsequent encounter for fracture with nonunion</p> <p>S22.42XS Multiple fractures of ribs, left side, sequela</p> <p>S22.43XA Multiple fractures of ribs, bilateral, initial encounter for closed fracture</p> <p>S22.43XD Multiple fractures of ribs, bilateral, subsequent encounter for fracture with routine healing</p> <p>S22.43XG Multiple fractures of ribs, bilateral, subsequent encounter for fracture with delayed healing</p> <p>S22.43XK Multiple fractures of ribs, bilateral, subsequent encounter for fracture with nonunion</p> <p>S22.43XS Multiple fractures of ribs, bilateral, sequela</p> <p>S22.49XA Multiple fractures of ribs, unspecified side, initial encounter for closed fracture</p> <p>S22.49XD Multiple fractures of ribs, unspecified side, subsequent encounter for fracture with routine healing</p> <p>S22.49XG Multiple fractures of ribs, unspecified side, subsequent encounter for fracture with delayed healing</p> <p>S22.49XK Multiple fractures of ribs, unspecified side, subsequent encounter for fracture with nonunion</p> <p>S22.49XS Multiple fractures of ribs, unspecified side, sequela</p>
Closed fracture of neck of femur (disorder)	<p>S72.001A Fracture of unspecified part of neck of right femur, initial encounter for closed fracture</p> <p>S72.001D Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with routine healing</p> <p>S72.001G Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with delayed healing</p> <p>S72.001K Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with nonunion</p> <p>S72.001P Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with malunion</p> <p>S72.002A Fracture of unspecified part of neck of left femur, initial encounter for closed fracture</p> <p>S72.002D Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with routine healing</p>

	<p>S72.002G Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with delayed healing</p> <p>S72.002K Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with nonunion</p> <p>S72.002P Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with malunion</p> <p>S72.002S Fracture of unspecified part of neck of left femur, sequela</p> <p>S72.009A Fracture of unspecified part of neck of unspecified femur, initial encounter for closed fracture</p> <p>S72.009D Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with routine healing</p> <p>S72.009G Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with delayed healing</p> <p>S72.009K Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with nonunion</p> <p>S72.009P Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with malunion</p> <p>S72.009S Fracture of unspecified part of neck of unspecified femur, sequela</p>
Closed fracture of right forearm (disorder)	<p>S52.91XA Unspecified fracture of right forearm, initial encounter for closed fracture</p> <p>S52.91XD Unspecified fracture of right forearm, subsequent encounter for closed fracture with routine healing</p> <p>S52.91XG Unspecified fracture of right forearm, subsequent encounter for closed fracture with delayed healing</p> <p>S52.91XK Unspecified fracture of right forearm, subsequent encounter for closed fracture with nonunion</p> <p>S52.91XP Unspecified fracture of right forearm, subsequent encounter for closed fracture with malunion</p> <p>S52.91XS Unspecified fracture of right forearm, sequela</p>
Clostridial enteric disease (disorder)	<p>A04.71 Enterocolitis due to Clostridium difficile, recurrent</p> <p>A04.72 Enterocolitis due to Clostridium difficile, not specified as recurrent</p>
Colostomy malfunction (disorder)	K94.03 Colostomy malfunction
Colostomy status	Z93.3 Colostomy status

Concussion with no loss of consciousness (disorder)	S06.0X0A Concussion without loss of consciousness, initial encounter S06.0X0D Concussion without loss of consciousness, subsequent encounter S06.0X0S Concussion without loss of consciousness, sequela
Condyloma latum (disorder)	A51.31 Condyloma latum
Contusion of lower back (disorder)	S30.0XXA Contusion of lower back and pelvis, initial encounter S30.0XXD Contusion of lower back and pelvis, subsequent encounter S30.0XXS Contusion of lower back and pelvis, sequela
Contusion of pelvic region (disorder)	S30.0XXA Contusion of lower back and pelvis, initial encounter S30.0XXD Contusion of lower back and pelvis, subsequent encounter S30.0XXS Contusion of lower back and pelvis, sequela
Contusion of scalp (disorder)	S00.03XA Contusion of scalp, initial encounter S00.03XD Contusion of scalp, subsequent encounter S00.03XS Contusion of scalp, sequela
Crohn's disease of small intestine with rectal bleeding	K50.011 Crohn's disease of small intestine with rectal bleeding
Cuff dehiscence	T81.30XA Disruption of wound, unspecified, initial encounter T81.30XD Disruption of wound, unspecified, subsequent encounter T81.30XS Disruption of wound, unspecified, sequela
Cutaneous abscess of abdominal wall	L02.211 Cutaneous abscess of abdominal wall
Cutaneous abscess of left upper limb	L02.414 Cutaneous abscess of left upper limb
Cutaneous abscess of neck	L02.11 Cutaneous abscess of neck
Cutaneous abscess of right upper limb	L02.413 Cutaneous abscess of right upper limb
Dehydration (disorder)	E86.0 Dehydration
Diaphragmatic hernia (disorder)	K44.0 Diaphragmatic hernia with obstruction, without gangrene K44.1 Diaphragmatic hernia with gangrene K44.9 Diaphragmatic hernia without obstruction or gangrene
Diaphragmatic hernia with gangrene (disorder)	K44.1 Diaphragmatic hernia with gangrene
Dysplasia of anus (disorder)	K62.82 Dysplasia of anus
Encounter for adjustment and management of vascular access device	Z45.2 Encounter for adjustment and management of vascular access device

Encounter for general adult medical examination	Z00.00 Encounter for general adult medical examination without abnormal findings Z00.01 Encounter for general adult medical examination with abnormal findings
Encounter for screening of malignant neoplasm of colon	Z12.11 Encounter for screening for malignant neoplasm of colon
Endometriosis of pelvic peritoneum (disorder)	N80.3 Endometriosis of pelvic peritoneum
Enterostomy malfunction (disorder)	K94.13 Enterostomy malfunction
Essential (primary) hypertension	I10 Essential (primary) hypertension
Family history of malignant neoplasm of brain (situation)	Z80.8 Family history of malignant neoplasm of other organs or systems
Family history of malignant neoplasm of digestive organ (situation)	Z80.0 Family history of malignant neoplasm of digestive organs
Female cystocele (disorder)	N81.10 Cystocele, unspecified N81.11 Cystocele, midline N81.12 Cystocele, lateral
Fistula of intestine (disorder)	K63.2 Fistula of intestine
Fistula of stomach and duodenum	K31.6 Fistula of stomach and duodenum
Follicular cyst of skin and subcutaneous tissue	L72.9 Follicular cyst of the skin and subcutaneous tissue, unspecified
Gastric ulcer (disorder)	K25.9 Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation
Gastroesophageal reflux disease without esophagitis (disorder)	K21.9 Gastro-esophageal reflux disease without esophagitis
Gastrointestinal hemorrhage (disorder)	K92.2 Gastrointestinal hemorrhage, unspecified
Gastroparesis (disorder)	K31.84 Gastroparesis
Gastroptosis (disorder)	K31.89 Other diseases of stomach and duodenum
Genital lichen sclerosus (disorder)	D07.1 Carcinoma in situ of vulva L90.0 Lichen sclerosus et atrophicus N48.0 Leukoplakia of penis N90.4 Leukoplakia of vulva
Genital Molluscum contagiosum	B08.1 Molluscum contagiosum
Hemorrhage of anus and rectum	K62.5 Hemorrhage of anus and rectum
HGSIL pap smear	R87.613 High grade squamous intraepithelial lesion on cytologic smear of cervix (HGSIL)
Hidradenitis suppurativa (disorder)	L73.2 Hidradenitis suppurativa
Hidradenitis suppurativa of anus (disorder)	L73.2 Hidradenitis suppurativa
Idiopathic normal pressure hydrocephalus	G91.2 (Idiopathic) normal pressure hydrocephalus

Ileostomy status	Z93.2 Ileostomy status
Immune thrombocytopenic purpura	D69.3 Immune thrombocytopenic purpura
Infection of skin caused by Molluscum contagiosum (disorder)	B08.1 Molluscum contagiosum H01.8 Other specified inflammations of eyelid
Injury of anal canal (disorder)	K64.8 Other hemorrhoids L08.9 Local infection of the skin and subcutaneous tissue, unspecified S30.827A Blister (nonthermal) of anus, initial encounter S30.827D Blister (nonthermal) of anus, subsequent encounter S30.827S Blister (nonthermal) of anus, sequela S30.867A Insect bite (nonvenomous) of anus, initial encounter S30.867D Insect bite (nonvenomous) of anus, subsequent encounter S30.867S Insect bite (nonvenomous) of anus, sequela S36.60XA Unspecified injury of rectum, initial encounter S36.60XD Unspecified injury of rectum, subsequent encounter S36.60XS Unspecified injury of rectum, sequela
Intestinal volvulus (disorder)	K56.2 Volvulus
Intestinovesical fistula (disorder)	N32.1 Vesicointestinal fistula N32.2 Vesical fistula, not elsewhere classified
Ischiorectal abscess (disorder)	K61.39 Other ischiorectal abscess
Jaundice (finding)	R17 Unspecified jaundice
Laceration of lower back without foreign body (disorder)	S31.010A Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, initial encounter S31.010D Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, subsequent encounter S31.010S Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, sequela
Laceration of pelvis without foreign body (disorder)	S31.010A Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, initial encounter S31.010D Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, subsequent encounter S31.010S Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, sequela

LGSIL pap smear	R87.612 Low grade squamous intraepithelial lesion on cytologic smear of cervix (LGSIL)
Low malignant potential (LMP) tumor of ovary	D39.10 Neoplasm of uncertain behavior of unspecified ovary D39.11 Neoplasm of uncertain behavior of right ovary D39.12 Neoplasm of uncertain behavior of left ovary
Lymphadenitis (disorder)	I88.9 Nonspecific lymphadenitis, unspecified
Malignant neoplasm of anus	C21.0 Malignant neoplasm of anus, unspecified
Malignant neoplasm of body of uterus (disorder)	C54.9 Malignant neoplasm of corpus uteri, unspecified
Malignant neoplasm of cecum	C18.0 Malignant neoplasm of cecum
Malignant neoplasm of cornu of corpus uteri (disorder)	C54.9 Malignant neoplasm of corpus uteri, unspecified
Malignant neoplasm of endometrium	C54.1 Malignant neoplasm of endometrium
Malignant neoplasm of fundus of corpus uteri (disorder)	C54.3 Malignant neoplasm of fundus uteri
Malignant neoplasm of isthmus of uterine body (disorder)	C54.0 Malignant neoplasm of isthmus uteri
Malignant neoplasm of lower lobe, unspecified bronchus or lung	C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung
Malignant neoplasm of myometrium of corpus uteri (disorder)	C54.2 Malignant neoplasm of myometrium
Malignant neoplasm of overlapping sites of unspecified female breast	C50.819 Malignant neoplasm of overlapping sites of unspecified female breast
Malignant neoplasm of urinary organ (disorder)	C68.8 Malignant neoplasm of overlapping sites of urinary organs C68.9 Malignant neoplasm of urinary organ, unspecified
Malignant neoplasm of uterine adnexa (disorder)	C57.4 Malignant neoplasm of uterine adnexa, unspecified
Malignant tumor of fallopian tube (disorder)	C57.00 Malignant neoplasm of unspecified fallopian tube C57.01 Malignant neoplasm of right fallopian tube C57.02 Malignant neoplasm of left fallopian tube
Malignant tumor of splenic flexure (disorder)	C18.5 Malignant neoplasm of splenic flexure
Melena (disorder)	K92.1 Melena
Molluscum contagiosum infection	B08.1 Molluscum contagiosum
Necrotizing fasciitis (disorder)	M72.6 Necrotizing fasciitis
Neoplasm of low malignant potential behavior of ovary (disorder)	D39.10 Neoplasm of uncertain behavior of unspecified ovary

	D39.11 Neoplasm of uncertain behavior of right ovary D39.12 Neoplasm of uncertain behavior of left ovary
Neoplasm of ovary (disorder)	C56.1 Malignant neoplasm of right ovary C56.2 Malignant neoplasm of left ovary C56.3 Malignant neoplasm of bilateral ovaries C56.9 Malignant neoplasm of unspecified ovary
Neoplasm of uncertain behavior of anal canal (disorder)	D37.8 Neoplasm of uncertain behavior of other specified digestive organs
Neoplasm of uncertain behavior of anal canal and sphincter (disorder)	D37.8 Neoplasm of uncertain behavior of other specified digestive organs
Neoplasm of uncertain behavior of appendix (disorder)	D37.3 Neoplasm of uncertain behavior of appendix
Neoplasm of uncertain behavior of colon (disorder)	D37.4 Neoplasm of uncertain behavior of colon
Neoplasm of uncertain behavior of stomach (disorder)	D37.1 Neoplasm of uncertain behavior of stomach
Neoplasm of uncertain behavior of rectum (disorder)	D37.5 Neoplasm of uncertain behavior of rectum
Neoplasm of uncertain behavior of retroperitoneum (disorder)	D48.3 Neoplasm of uncertain behavior of retroperitoneum
Nontraumatic acute subdural hemorrhage	I62.01 Nontraumatic acute subdural hemorrhage
Nontraumatic hematoma of soft tissue (disorder)	M79.81 Nontraumatic hematoma of soft tissue
Nontraumatic hemoperitoneum (disorder)	K66.1 Hemoperitoneum
Nontraumatic intracranial hemorrhage	I62.9 Nontraumatic intracranial hemorrhage, unspecified
Obstructive hydrocephalus (disorder)	G91.1 Obstructive hydrocephalus
Outlet dysfunction constipation	K59.02 Outlet dysfunction constipation
Paralytic ileus (disorder)	K56.0 Paralytic ileus
Partial obstruction of intestine (disorder)	K56.600 Partial intestinal obstruction, unspecified as to cause K56.690 Other partial intestinal obstruction
Pelvic hematoma (disorder)	M79.81 Nontraumatic hematoma of soft tissue N48.89 Other specified disorders of penis
Perforation of intestine (disorder)	K63.1 Perforation of intestine
Perianal lump (finding)	R22.2 Localized swelling, mass and lump, trunk
Peripheral neuropathy	G90.09 Other idiopathic peripheral autonomic neuropathy
Peritoneal adhesion (disorder)	K66.0 Peritoneal adhesions (postprocedural) (postinfection)

Personal history of colonic polyps	Z86.010 Personal history of colonic polyps
Pilonidal cyst with abscess	L05.01 Pilonidal cyst with abscess
Pouchitis	K91.850 Pouchitis
Primary malignant neoplasm of left ovary (disorder)	C56.2 Malignant neoplasm of left ovary
Primary malignant neoplasm of lower lobe, bronchus or lung (disorder)	C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung
Primary malignant neoplasm of ovary (disorder)	C56.1 Malignant neoplasm of right ovary C56.2 Malignant neoplasm of left ovary C56.3 Malignant neoplasm of bilateral ovaries C56.9 Malignant neoplasm of unspecified ovary
Primary malignant neoplasm of rectosigmoid junction (disorder)	C19 Malignant neoplasm of rectosigmoid junction
Primary malignant neoplasm of right ovary (disorder)	C56.1 Malignant neoplasm of right ovary
Primary malignant neoplasm of sigmoid colon (disorder)	C18.7 Malignant neoplasm of sigmoid colon
Primary overlapping malignant neoplasm of female left breast (disorder)	C50.812 Malignant neoplasm of overlapping sites of left female breast
Primary overlapping malignant neoplasm of female right breast (disorder)	C50.811 Malignant neoplasm of overlapping sites of right female breast
Proctodynia (finding)	K62.89 Other specified diseases of anus and rectum
Proctoptosis (disorder)	K62.3 Rectal prolapse
Prolapse of intestine (disorder)	K63.4 Enteroptosis
Pruritus ani (disorder)	L29.0 Pruritus ani
Puncture wound without foreign body, left lower leg	S81.832A Puncture wound without foreign body, left lower leg, initial encounter S81.832D Puncture wound without foreign body, left lower leg, subsequent encounter S81.832S Puncture wound without foreign body, left lower leg, sequela
Puncture wound without foreign body, right lower leg	S81.831A Puncture wound without foreign body, right lower leg, initial encounter S81.831D Puncture wound without foreign body, right lower leg, subsequent encounter S81.831S Puncture wound without foreign body, right lower leg, sequela
Puncture wound without foreign body, unspecified lower leg	S81.839A Puncture wound without foreign body, unspecified lower leg, initial encounter S81.839D Puncture wound without foreign body, unspecified lower leg, subsequent encounter S81.839S Puncture wound without foreign body, unspecified lower leg, sequela

Radiation proctitis (disorder)	K62.7 Radiation proctitis W90.8XXA Exposure to other nonionizing radiation, initial encounter W90.8XXD Exposure to other nonionizing radiation, subsequent encounter W90.8XXS Exposure to other nonionizing radiation, sequela
Rectal abscess (disorder)	K61.1 Rectal abscess
Rectal cancer	C20 Malignant neoplasm of rectum
Rectal polyp (disorder)	K62.1 Rectal polyp
Rectocele	N81.6 Rectocele
Residual hemorrhoidal skin tags (disorder)	K64.4 Residual hemorrhoidal skin tags
Sebaceous cyst of penis (disorder)	N48.89 Other specified disorders of penis
Sebaceous cyst of scrotum (disorder)	L72.3 Sebaceous cyst
Sebaceous cyst of skin (disorder)	L72.3 Sebaceous cyst
Sebaceous cyst of skin of bilateral breasts (disorder)	N60.81 Other benign mammary dysplasias of right breast N60.82 Other benign mammary dysplasias of left breast N60.89 Other benign mammary dysplasias of unspecified breast
Sebaceous cyst of skin of breast (disorder)	N60.81 Other benign mammary dysplasias of right breast N60.82 Other benign mammary dysplasias of left breast N60.89 Other benign mammary dysplasias of unspecified breast
Skin lesion (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Stenosis of anal canal (disorder)	K62.4 Stenosis of anus and rectum
Stenosis of rectum (disorder)	K62.4 Stenosis of anus and rectum
Stenosis of rectum and anus (disorder)	K62.4 Stenosis of rectum and anus
Subacute non-traumatic intracranial subdural hemorrhage	I62.01 Nontraumatic subacute subdural hemorrhage
Thrombocytopenia, unspecified	D69.6 Thrombocytopenia, unspecified
Unspecified B-cell lymphoma	C85.10 Unspecified B-cell lymphoma, unspecified site C85.11 Unspecified B-cell lymphoma, lymph nodes of head, face, and neck C85.12 Unspecified B-cell lymphoma, intrathoracic lymph nodes C85.13 Unspecified B-cell lymphoma, intra-abdominal lymph nodes

	<p>C85.14 Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb</p> <p>C85.15 Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb</p> <p>C85.16 Unspecified B-cell lymphoma, intrapelvic lymph nodes</p> <p>C85.17 Unspecified B-cell lymphoma, spleen</p> <p>C85.18 Unspecified B-cell lymphoma, lymph nodes of multiple sites</p> <p>C85.19 Unspecified B-cell lymphoma, extranodal and solid organ sites</p> <p>C85.20 Mediastinal (thymic) large B-cell lymphoma, unspecified site</p>
Unspecified closed fracture of lumbar vertebra	<p>S32.009A Unspecified fracture of unspecified lumbar vertebra, initial encounter for closed fracture</p> <p>S32.009D Unspecified fracture of unspecified lumbar vertebra, subsequent encounter for fracture with routine healing</p> <p>S32.009G Unspecified fracture of unspecified lumbar vertebra, subsequent encounter for fracture with delayed healing</p> <p>S32.009K Unspecified fracture of unspecified lumbar vertebra, subsequent encounter for fracture with nonunion</p> <p>S32.009S Unspecified fracture of unspecified lumbar vertebra, sequela</p>
Unspecified closed fracture of unspecified forearm	<p>S52.90XA Unspecified fracture of unspecified forearm, initial encounter for closed fracture</p> <p>S52.90XD Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with routine healing</p> <p>S52.90XG Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with delayed healing</p> <p>S52.90XK Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with nonunion</p> <p>S52.90XP Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with malunion</p> <p>S52.90XS Unspecified fracture of unspecified forearm, sequela</p>
Vaginal enterocele (disorder)	N81.5 Vaginal enterocele
Vascular disorder of intestine (disorder)	K55.9 Vascular disorder of intestine, unspecified
Ventral hernia without obstruction or gangrene	K43.9 Ventral hernia without obstruction or gangrene
Vulval pain (finding)	<p>N94.818 Other vulvodynia</p> <p>N94.819 Vulvodynia, unspecified</p>

Vulvodynia (disorder)	N94.818 Other vulvodynia N94.819 Vulvodynia, unspecified
Wound (disorder)	T14.8XXA Other injury of unspecified body region, initial encounter T14.8XXD Other injury of unspecified body region, subsequent encounter T14.8XXS Other injury of unspecified body region, sequela

Appendix B

Regimen Consolidation Summary

Updates

The following regimens have been created as part of the Reference/Biosimilar Merge initiative.

- Bevacizumab (5 mg/kg) Q14D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab (7.5 mg/kg) Q21D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab (15 mg/kg) + Erlotinib Q21D
- Bevacizumab (15 mg/kg) Q21D
- Bevacizumab D1,15 + Cyclophosphamide PO Q28D
- Bevacizumab D1,15 Q28D
- Bevacizumab Q14D (RCC)
- Capecitabine D1-14 + Bevacizumab Q21D
- Capecitabine D1-14 + Irinotecan (XELIRI/CAPIRI) + Bevacizumab Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Bevacizumab Q21D
- Carboplatin + Liposomal Doxorubicin + Bevacizumab D1,15 Q28D
- Darbepoetin alfa Q28D (Chronic Kidney Disease not on Dialysis)
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin (Simplified) + Bevacizumab Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Bevacizumab Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Bevacizumab Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin D1-2 (De Gramont) + Bevacizumab Q14D
- Fluorouracil Bolus D1,8,15,22,29,36 + Leucovorin D1,8,15,22,29,36 (Roswell Park) + Bevacizumab D1,15,29,43 Q56D
- Fluorouracil Bolus D1-5 + Leucovorin D1-5 (Mayo) + Bevacizumab D1,15 Q28D
- FOLFIRINOX (Modified) + Bevacizumab Q14D
- FOLFIRINOX + Bevacizumab Q14D
- FOLFOXIRI + Bevacizumab Q14D
- Gemcitabine D1,8 + Carboplatin + Bevacizumab Q21D
- Irinotecan + Bevacizumab Q14D
- Leuprolide Q28D (Breast Cancer)
- Liposomal Doxorubicin + Bevacizumab D1,15 Q28D

- Luspatercept-aamt Q21D (MDS)
- Olaparib + Bevacizumab Q21D
- Paclitaxel + Carboplatin (AUC 5) + Bevacizumab (15 mg/kg) Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (7.5 mg/kg) Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (15 mg/kg) Q21D (Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (7.5 mg/kg) Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (15 mg/kg) Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical)
- Paclitaxel + Carboplatin + Bevacizumab Q21D (NSCLC)
- Paclitaxel + Cisplatin + Bevacizumab Q21D
- Paclitaxel + Topotecan D1-3 + Bevacizumab Q21D
- Paclitaxel D1,8,15,22 + Bevacizumab D1,15 Q28D (Ovarian)
- Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab Q21D (Cervical)
- Pemetrexed + Bevacizumab (15 mg/kg) Q21D (Maintenance)
- Pemetrexed + Carboplatin + Bevacizumab Q21D
- Pemetrexed + Cisplatin + Bevacizumab Q21D (Mesothelioma)
- Topotecan D1,8,15 + Bevacizumab D1,15 Q28D
- Topotecan D1-5 + Bevacizumab Q21D
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab D1,15 Q28D

Removals

The following regimens have been inactivated as part of the Reference Regimen / Biosimilar Merge initiative.

- Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction) Reference
- Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab + Bevacizumab Maintenance) Reference
- Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction)
- Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab + Bevacizumab Maintenance)
- Atezolizumab + Bevacizumab BIOSIMILAR Q21D
- Atezolizumab + Bevacizumab Q21D Reference
- Bevacizumab (15 mg/kg) + Erlotinib Q21D Reference
- Bevacizumab (15 mg/kg) BIOSIMILAR + Erlotinib Q21D)
- Bevacizumab (15 mg/kg) BIOSIMILAR Q21D
- Bevacizumab (15 mg/kg) Q21D Reference
- Bevacizumab (5 mg/kg) BIOSIMILAR Q14D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab (7.5 mg/kg) BIOSIMILAR Q21D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab BIOSIMILAR D1,15 + Cyclophosphamide PO Q28D
- Bevacizumab BIOSIMILAR D1,15 Q28D

- Bevacizumab BIOSIMILAR Q14D (RCC)
- Bevacizumab D1,15 + Cyclophosphamide PO Q28D Reference
- Bevacizumab D1,15 Q28D Reference
- Bevacizumab Q14D (RCC) Reference
- Capecitabine D1-14 + Bevacizumab BIOSIMILAR Q21D
- Capecitabine D1-14 + Bevacizumab Q21D Reference
- Capecitabine D1-14 + Irinotecan (XELIRI/CAPIRI) + Bevacizumab BIOSIMILAR Q21D
- Capecitabine D1-14 + Irinotecan (XELIRI/CAPIRI) + Bevacizumab Q21D Reference
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Bevacizumab BIOSIMILAR Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Bevacizumab Q21D Reference
- Carboplatin + Liposomal Doxorubicin + Bevacizumab BIOSIMILAR D1,15 Q28D
- Carboplatin + Liposomal Doxorubicin + Bevacizumab D1,15 Q28D Reference
- Darbepoetin alfa Q28D (CKD not on Dialysis)
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin (Simplified) + Bevacizumab Q14D Reference
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin (Simplified) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Bevacizumab Q14D Reference
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Bevacizumab Q14D Reference
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin D1-2 (De Gramont) + Bevacizumab Q14D Reference
- Fluorouracil (Bolos + CIV) D1-2 + Leucovorin D1-2 (De Gramont) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil Bolus D1,8,15,22,29,36 + Leucovorin D1,8,15,22,29,36 (Roswell Park) + Bevacizumab D1,15,29,43 Q56D Reference
- Fluorouracil Bolus D1,8,15,22,29,36 + Leucovorin D1,8,15,22,29,36 (Roswell Park) + Bevacizumab BIOSIMILAR D1,15,29,43 Q56D
- Fluorouracil Bolus D1-5 + Leucovorin D1-5 (Mayo) + Bevacizumab BIOSIMILAR D1,15 Q28D
- Fluorouracil Bolus D1-5 + Leucovorin D1-5 (Mayo) + Bevacizumab D1,15 Q28D Reference
- FOLFIRINOX (Modified) + Bevacizumab BIOSIMILAR Q14D
- FOLFIRINOX (Modified) + Bevacizumab Q14D Reference
- FOLFIRINOX + Bevacizumab BIOSIMILAR Q14D
- FOLFIRINOX + Bevacizumab Q14D Reference
- FOLFOXIRI + Bevacizumab BIOSIMILAR Q14D
- FOLFOXIRI + Bevacizumab Q14D Reference
- Gemcitabine D1,8 + Carboplatin + Bevacizumab BIOSIMILAR Q21D
- Gemcitabine D1,8 + Carboplatin + Bevacizumab Q21D Reference
- Irinotecan + Bevacizumab BIOSIMILAR Q14D
- Irinotecan + Bevacizumab Q14D Reference
- Leuprolide Q28D (Breast)
- Liposomal Doxorubicin + Bevacizumab BIOSIMILAR D1,15 Q28D

- Liposomal Doxorubicin + Bevacizumab D1,15 Q28D Reference
- Luspatercept-aamt Q21D (MDS, Myelofibrosis)
- Olaparib + Bevacizumab BIOSIMILAR Q21D
- Olaparib + Bevacizumab Q21D Reference
- Paclitaxel + Carboplatin (AUC 5) + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 5) + Bevacizumab (15 mg/kg) Q21D (Ovarian) Reference
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (15 mg/kg) Q21D (Ovarian) Reference
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (7.5 mg/kg) BIOSIMILAR Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (7.5 mg/kg) Q21D (Ovarian) Reference
- Paclitaxel + Carboplatin + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (15 mg/kg) Q21D (Bevacizumab Continuation, Ovarian) Reference
- Paclitaxel + Carboplatin + Bevacizumab (7.5 mg/kg) BIOSIMILAR Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (7.5 mg/kg) Q21D (Bevacizumab Continuation, Ovarian) Reference
- Paclitaxel + Carboplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
- Paclitaxel + Carboplatin + Bevacizumab BIOSIMILAR Q21D (NSCLC)
- Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical) Reference
- Paclitaxel + Carboplatin + Bevacizumab Q21D (NSCLC) Reference
- Paclitaxel + Cisplatin + Bevacizumab BIOSIMILAR Q21D
- Paclitaxel + Cisplatin + Bevacizumab Q21D Reference
- Paclitaxel + Topotecan D1-3 + Bevacizumab BIOSIMILAR Q21D
- Paclitaxel + Topotecan D1-3 + Bevacizumab Q21D Reference
- Paclitaxel D1,8,15,22 + Bevacizumab BIOSIMILAR D1,15 Q28D (Ovarian)
- Paclitaxel D1,8,15,22 + Bevacizumab D1,15 Q28D (Ovarian) Reference
- Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical) Reference
- Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab Q21D (Cervical) Reference
- Pemetrexed + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Maintenance)
- Pemetrexed + Bevacizumab (15 mg/kg) Q21D (Maintenance) Reference
- Pemetrexed + Carboplatin + Bevacizumab BIOSIMILAR Q21D
- Pemetrexed + Carboplatin + Bevacizumab Q21D Reference
- Pemetrexed + Cisplatin + Bevacizumab BIOSIMILAR Q21D (Mesothelioma)
- Pemetrexed + Cisplatin + Bevacizumab Q21D (Mesothelioma) Reference
- Topotecan D1,8,15 + Bevacizumab BIOSIMILAR D1,15 Q28D
- Topotecan D1-5 + Bevacizumab BIOSIMILAR Q21D
- Topotecan D1-5 + Bevacizumab Q21D Reference
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab BIOSIMILAR D1,15 Q28D
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab D1,15 Q28D Reference